|Cancer continues to pose a major health burden worldwide. Prevailing therapies are extremely limited in terms of safety, tolerability, and efficacy. Meanwhile, the morbidity and mortality associated with cancer is fueling interest in novel therapeutic approaches. Foremost among these are therapies that enhance the ability of the body's own immune system to fight and destroy abnormal cancer cells. Anticancer vaccines and immune modulators, working in concert and as monotherapy, stole the show at ASCO last June, suggesting that after years of failure in the clinic their time has come. Cancer Immunotherapies and Vaccines: Pipeline Analysis and Competitive Dynamics , a CHI Insight Pharma report, surveys and assesses recent developments in this highly promising avenue of cancer therapy.
Numerous biopharmaceutical companies are working to develop approaches that harness the body's own immune system to fight cancer. Several monoclonal antibodies have already reached the market. This approach is sometimes referred to as passive immunotherapy. Our study focuses on active immunotherapies and vaccines that enhance the ability of the patient's own immune system to fight cancer.
SWOT Analysis of BiovaxID with Standard Therapy
for Treatment of Follicular Non-Hodgkin's Lymphoma
and Vaccines begins by reviewing the pathophysiology,
epidemiology, diagnosis, and current treatment options of
eight major cancers targeted by companies developing
immune modulating drugs and vaccines:
* breast cancer
* colorectal cancer
* pancreatic cancer
* lung cancer
* prostate cancer
* renal cancer
While no active cancer
targeted to a type of cancer) have reached the market, the
most advanced example is Dendreon's Provenge.
Dendreon is submitting a rolling BLA (Biologics License
Application) to the FDA for Provenge, for treatment of
advanced hormone-refractory prostate cancer. Clinical trial
data supporting this BLA, and available data on other
immunotherapies and vaccines, are assessed in the report.
Cancer Immunotherapies and Vaccines also provides:
An explanation of R&D challenges in the development of cancer immunotherapies and vaccines
The various technical approaches being used to develop active cancer immunotherapies and vaccines
The many emerging immune-based therapies that are currently being evaluated in clinical trials for these eight cancers
Interviews with six senior executives from leading companies in the field of cancer immunotherapies and vaccines who discuss the progress, the challenges and hurdles, faced by researchers
Pipeline projects of over 35 companies, including discontinued projects
Thirteen SWOT charts (strengths, weaknesses, opportunities, threats) comparing the most promising immunotherapies and vaccines with standard therapy in 6 major cancers
About the Author
Lucy J. Sannes, Ph.D., is president of Sannes & Associates, Inc., a consulting firm specializing in evaluation and management of the biosciences. Before forming Sannes & Associates, she held management positions at Genetic Systems and Abbott Laboratories in product development, product support, and technical marketing. Dr. Sannes received her Ph.D. in biological chemistry from the University of Michigan and her M.B.A. from Seattle Pacific University.